ZAGREB, April 27 (Hina) - Investments of Pliva, the largest eastern and central European pharmaceutical company, amounted to 969 million kuna (138 million US dollars) last year. The Pliva concern comprising ten companies earmarked
that money into tangible assets, the injection of fresh capital into subsidiaries, acquisition and the purchase of its own share, read a 1998 financial report by this firm. Last year the concern invested 438 million kuna (62.5 million dollars) into tangible assets. Most of these means ($11 million) were directed to the construction of a plant for the production of azithromycin, in Savski Marof, outside Zagreb. The plant began producing this blockbuster drug in the second half of the year. It spent $5.85 million in building another drug plant in Zagreb. The introduction of information system SAP/R3 cost Pliva $4.2 million. Pliva spent four million dollars
ZAGREB, April 27 (Hina) - Investments of Pliva, the largest eastern
and central European pharmaceutical company, amounted to 969
million kuna (138 million US dollars) last year.
The Pliva concern comprising ten companies earmarked that money
into tangible assets, the injection of fresh capital into
subsidiaries, acquisition and the purchase of its own share, read a
1998 financial report by this firm.
Last year the concern invested 438 million kuna (62.5 million
dollars) into tangible assets. Most of these means ($11 million)
were directed to the construction of a plant for the production of
azithromycin, in Savski Marof, outside Zagreb. The plant began
producing this blockbuster drug in the second half of the year.
It spent $5.85 million in building another drug plant in Zagreb.
The introduction of information system SAP/R3 cost Pliva $4.2
million.
Pliva spent four million dollars in research and the control of
quality last year.
(hina) ms